Search

Displaying results 3991 - 4000 of 10000 in total
  1. Drug

    Isoxicam

    go.drugbank.com/drugs/DB08942
    ApprovedWithdrawn

    Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  2. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  3. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated

  4. Drug

    Trichophyton rubrum

    go.drugbank.com/drugs/DB10915
    Approved

    Trichophyton rubrum is a fungus which can provoke allergic reactions. Trichophyton rubrum extract is used in allergenic testing.

    Mixtures: Trichophyton for Intradermal Skin TestingCategories: Non-Standardized Fungal Allergenic Extract
  5. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 … (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes).

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

  7. Drug

    LNP-nCoVsaRNA Vaccine

    go.drugbank.com/drugs/DB15799
    Experimental

    The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.

  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.

  9. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  10. Drug

    Fispemifene

    go.drugbank.com/drugs/DB06640
    Investigational